The ongoing evolution of global hormone therapy, combined with a significant rise in public and private investments in fertility care, has placed specialty pharmaceutical synthesis at the very center of modern healthcare manufacturing. As medical protocols for controlled ovarian hyperstimulation become increasingly refined, contract development and manufacturing organizations (CDMOs) require...